- Published on
Ophthalmology – Dry Age-Related Macular Degeneration (AMD)
Dry age-related macular degeneration is a chronic degenerative condition affecting the macula and is a major cause of vision loss in elderly populations, particularly among individuals of European descent. It primarily involves the outer retina, retinal pigment epithelium (RPE), Bruch’s membrane, and the choriocapillaris. Although it is less likely to cause rapid or severe vision loss compared to the wet (exudative) form, it still accounts for a significant proportion of legal blindness in patients over 65 years of age. The disease is characterized by the presence of drusen, pigmentary changes, and in advanced stages, geographic atrophy.
The incidence and prevalence of dry AMD increase with age, with early disease affecting millions of individuals. The development of large drusen or pigmentary changes occurs more frequently in older age groups, and progression to advanced AMD, including geographic atrophy or neovascular AMD, becomes more likely with advancing age. Risk factors include increasing age, family history, Caucasian ethnicity, smoking, and possibly cardiovascular risk factors. Genetic predisposition plays a significant role, with variants in genes such as complement factor H (CFH), complement factor B, and HTRA1 contributing to disease susceptibility.
The pathophysiology involves degenerative changes in the RPE and Bruch’s membrane, with accumulation of metabolic waste products and formation of drusen. These deposits may be classified as hard or soft drusen, with soft drusen being more strongly associated with disease progression. Over time, dysfunction and loss of the RPE can lead to photoreceptor degeneration and geographic atrophy. Oxidative stress and accumulation of lipofuscin components, such as A2E, are thought to contribute to RPE cell death and disease progression.
Patients with early dry AMD are often asymptomatic and may be diagnosed during routine examination. As the disease progresses, symptoms may include gradual central vision loss, distortion (metamorphopsia), or the appearance of central scotomas. The condition is typically bilateral but often asymmetric. Sudden worsening of vision or distortion may indicate progression to the exudative form and requires urgent evaluation.
On examination, characteristic findings include drusen of varying size and appearance, pigmentary changes in the RPE, and areas of retinal thinning or atrophy. Geographic atrophy appears as well-defined areas of RPE loss, while earlier changes may include mottled pigmentation. The classification of AMD into early, intermediate, and advanced stages is based on the size and extent of drusen and the presence of atrophy or neovascular changes.
Diagnosis and monitoring rely on imaging techniques such as optical coherence tomography, which can identify drusen, RPE abnormalities, and areas of atrophy, as well as detect early signs of progression to wet AMD. Fluorescein angiography may be used in cases of suspected neovascularization, and fundus autofluorescence can help assess RPE health and areas of damage. Risk of progression can be estimated using the AREDS simplified severity score, which incorporates features such as large drusen, pigmentary abnormalities, and involvement of both eyes.
Management focuses on slowing disease progression and monitoring for complications. The Age-Related Eye Disease Study demonstrated that antioxidant vitamin supplementation, including vitamins C and E, zinc, beta-carotene, and copper, can reduce the risk of progression in patients with intermediate or advanced AMD. However, beta-carotene should be avoided in smokers due to increased risk of lung cancer. Lifestyle modifications, particularly smoking cessation and a diet rich in leafy green vegetables and omega-3 fatty acids, are strongly recommended. Patients should also be advised to regularly monitor their vision using an Amsler grid to detect early changes suggestive of progression.
There is no role for laser photocoagulation in dry AMD, and current management is largely supportive. Regular ophthalmologic follow-up is essential to monitor disease progression and detect conversion to the wet form, which requires different treatment. The prognosis varies, with many patients maintaining functional vision for years, although some will progress to advanced stages with significant central vision loss.
Dry age-related macular degeneration is a chronic degenerative condition affecting the macula and is a major cause of vision loss in elderly populations, particularly among individuals of European descent. It primarily involves the outer retina, retinal pigment epithelium (RPE), Bruch’s membrane, and the choriocapillaris. Although it is less likely to cause rapid or severe vision loss compared to the wet (exudative) form, it still accounts for a significant proportion of legal blindness in patients over 65 years of age. The disease is characterized by the presence of drusen, pigmentary changes, and in advanced stages, geographic atrophy.
The incidence and prevalence of dry AMD increase with age, with early disease affecting millions of individuals. The development of large drusen or pigmentary changes occurs more frequently in older age groups, and progression to advanced AMD, including geographic atrophy or neovascular AMD, becomes more likely with advancing age. Risk factors include increasing age, family history, Caucasian ethnicity, smoking, and possibly cardiovascular risk factors. Genetic predisposition plays a significant role, with variants in genes such as complement factor H (CFH), complement factor B, and HTRA1 contributing to disease susceptibility.
The pathophysiology involves degenerative changes in the RPE and Bruch’s membrane, with accumulation of metabolic waste products and formation of drusen. These deposits may be classified as hard or soft drusen, with soft drusen being more strongly associated with disease progression. Over time, dysfunction and loss of the RPE can lead to photoreceptor degeneration and geographic atrophy. Oxidative stress and accumulation of lipofuscin components, such as A2E, are thought to contribute to RPE cell death and disease progression.
Patients with early dry AMD are often asymptomatic and may be diagnosed during routine examination. As the disease progresses, symptoms may include gradual central vision loss, distortion (metamorphopsia), or the appearance of central scotomas. The condition is typically bilateral but often asymmetric. Sudden worsening of vision or distortion may indicate progression to the exudative form and requires urgent evaluation.
On examination, characteristic findings include drusen of varying size and appearance, pigmentary changes in the RPE, and areas of retinal thinning or atrophy. Geographic atrophy appears as well-defined areas of RPE loss, while earlier changes may include mottled pigmentation. The classification of AMD into early, intermediate, and advanced stages is based on the size and extent of drusen and the presence of atrophy or neovascular changes.
Diagnosis and monitoring rely on imaging techniques such as optical coherence tomography, which can identify drusen, RPE abnormalities, and areas of atrophy, as well as detect early signs of progression to wet AMD. Fluorescein angiography may be used in cases of suspected neovascularization, and fundus autofluorescence can help assess RPE health and areas of damage. Risk of progression can be estimated using the AREDS simplified severity score, which incorporates features such as large drusen, pigmentary abnormalities, and involvement of both eyes.
Management focuses on slowing disease progression and monitoring for complications. The Age-Related Eye Disease Study demonstrated that antioxidant vitamin supplementation, including vitamins C and E, zinc, beta-carotene, and copper, can reduce the risk of progression in patients with intermediate or advanced AMD. However, beta-carotene should be avoided in smokers due to increased risk of lung cancer. Lifestyle modifications, particularly smoking cessation and a diet rich in leafy green vegetables and omega-3 fatty acids, are strongly recommended. Patients should also be advised to regularly monitor their vision using an Amsler grid to detect early changes suggestive of progression.
There is no role for laser photocoagulation in dry AMD, and current management is largely supportive. Regular ophthalmologic follow-up is essential to monitor disease progression and detect conversion to the wet form, which requires different treatment. The prognosis varies, with many patients maintaining functional vision for years, although some will progress to advanced stages with significant central vision loss.
- Published on
Ophthalmology – Allergic Conjunctivitis
Allergic conjunctivitis is an inflammatory condition of the ocular surface caused by hypersensitivity reactions to environmental allergens and is one of the most common eye disorders, affecting up to 40% of the population. It encompasses several subtypes, including seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). SAC occurs during specific times of the year, typically related to pollen exposure, while PAC persists year-round due to indoor allergens such as dust mites or animal dander. VKC and AKC are more severe, chronic forms often involving the cornea, and GPC is typically associated with mechanical irritation, such as contact lens wear or ocular prostheses.
The condition is strongly associated with atopic disease, including asthma, eczema, allergic rhinitis, and hay fever, and often occurs in individuals with a personal or family history of these conditions. VKC tends to affect young males in warm climates and often improves after puberty, whereas AKC occurs in older individuals and is associated with atopic dermatitis. GPC is linked to chronic mechanical irritation rather than classic allergy alone. The underlying pathophysiology involves activation of mast cells in response to allergens, leading to release of histamine and other inflammatory mediators. SAC and PAC are primarily type I hypersensitivity reactions, while VKC and AKC involve both type I and type IV hypersensitivity mechanisms.
Patients commonly present with itching, which is the hallmark symptom, along with redness, tearing, burning, photophobia, and watery discharge. SAC symptoms typically correlate with seasonal allergen exposure, while PAC symptoms are more persistent. VKC presents with intense itching and is often bilateral, while AKC may have chronic symptoms with associated eyelid dermatitis. GPC is often associated with contact lens intolerance and mucous discharge. On examination, SAC and PAC show mild conjunctival injection and papillary reactions without large papillae. VKC is characterized by giant papillae on the upper tarsal conjunctiva, limbal thickening, and Trantas’ dots, with possible corneal involvement such as punctate keratopathy or shield ulcers. AKC may show eyelid eczema, papillary hypertrophy, and corneal scarring or pannus. GPC presents with large papillae on the superior tarsal conjunctiva.
Diagnosis is primarily clinical and does not usually require laboratory testing, although conjunctival scrapings may reveal eosinophils. Differential diagnoses include viral conjunctivitis, dry eye disease, blepharitis, contact dermatitis, toxic or chemical conjunctivitis, and floppy eyelid syndrome. Management focuses on allergen avoidance and symptom control. First-line treatment for mild cases includes topical antihistamines, mast cell stabilizers, or combination agents such as olopatadine or ketotifen. Artificial tears can help dilute allergens and soothe the ocular surface. In more severe cases, especially VKC and AKC, topical corticosteroids may be required but should be used cautiously due to potential side effects such as glaucoma, cataract formation, and increased risk of infection. Topical cyclosporine may be used in chronic or steroid-dependent cases.
For GPC, management includes improving contact lens hygiene, reducing lens wear, or temporarily discontinuing lens use. Additional supportive measures include avoiding known triggers, staying in cool environments, and using preservative-free artificial tears frequently. Patients with significant corneal involvement or vision-threatening complications should be referred to an ophthalmologist for specialized care. Surgical interventions, such as superficial keratectomy or tarsorrhaphy, may be required in severe refractory cases.
The prognosis is generally good for SAC, PAC, and GPC, with symptoms being manageable and often intermittent. However, VKC and AKC can have a more guarded prognosis due to potential corneal complications, including scarring and vision loss. Regular follow-up is important in these cases, particularly when using topical steroids, to monitor intraocular pressure and lens clarity.
Allergic conjunctivitis is an inflammatory condition of the ocular surface caused by hypersensitivity reactions to environmental allergens and is one of the most common eye disorders, affecting up to 40% of the population. It encompasses several subtypes, including seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis (GPC). SAC occurs during specific times of the year, typically related to pollen exposure, while PAC persists year-round due to indoor allergens such as dust mites or animal dander. VKC and AKC are more severe, chronic forms often involving the cornea, and GPC is typically associated with mechanical irritation, such as contact lens wear or ocular prostheses.
The condition is strongly associated with atopic disease, including asthma, eczema, allergic rhinitis, and hay fever, and often occurs in individuals with a personal or family history of these conditions. VKC tends to affect young males in warm climates and often improves after puberty, whereas AKC occurs in older individuals and is associated with atopic dermatitis. GPC is linked to chronic mechanical irritation rather than classic allergy alone. The underlying pathophysiology involves activation of mast cells in response to allergens, leading to release of histamine and other inflammatory mediators. SAC and PAC are primarily type I hypersensitivity reactions, while VKC and AKC involve both type I and type IV hypersensitivity mechanisms.
Patients commonly present with itching, which is the hallmark symptom, along with redness, tearing, burning, photophobia, and watery discharge. SAC symptoms typically correlate with seasonal allergen exposure, while PAC symptoms are more persistent. VKC presents with intense itching and is often bilateral, while AKC may have chronic symptoms with associated eyelid dermatitis. GPC is often associated with contact lens intolerance and mucous discharge. On examination, SAC and PAC show mild conjunctival injection and papillary reactions without large papillae. VKC is characterized by giant papillae on the upper tarsal conjunctiva, limbal thickening, and Trantas’ dots, with possible corneal involvement such as punctate keratopathy or shield ulcers. AKC may show eyelid eczema, papillary hypertrophy, and corneal scarring or pannus. GPC presents with large papillae on the superior tarsal conjunctiva.
Diagnosis is primarily clinical and does not usually require laboratory testing, although conjunctival scrapings may reveal eosinophils. Differential diagnoses include viral conjunctivitis, dry eye disease, blepharitis, contact dermatitis, toxic or chemical conjunctivitis, and floppy eyelid syndrome. Management focuses on allergen avoidance and symptom control. First-line treatment for mild cases includes topical antihistamines, mast cell stabilizers, or combination agents such as olopatadine or ketotifen. Artificial tears can help dilute allergens and soothe the ocular surface. In more severe cases, especially VKC and AKC, topical corticosteroids may be required but should be used cautiously due to potential side effects such as glaucoma, cataract formation, and increased risk of infection. Topical cyclosporine may be used in chronic or steroid-dependent cases.
For GPC, management includes improving contact lens hygiene, reducing lens wear, or temporarily discontinuing lens use. Additional supportive measures include avoiding known triggers, staying in cool environments, and using preservative-free artificial tears frequently. Patients with significant corneal involvement or vision-threatening complications should be referred to an ophthalmologist for specialized care. Surgical interventions, such as superficial keratectomy or tarsorrhaphy, may be required in severe refractory cases.
The prognosis is generally good for SAC, PAC, and GPC, with symptoms being manageable and often intermittent. However, VKC and AKC can have a more guarded prognosis due to potential corneal complications, including scarring and vision loss. Regular follow-up is important in these cases, particularly when using topical steroids, to monitor intraocular pressure and lens clarity.
- Published on
Ophthalmology – Albinism
Albinism refers to a group of inherited disorders characterized by reduced or absent melanin production due to defects in melanin synthesis or melanosome formation. It is broadly classified into oculocutaneous albinism (OCA), which affects the skin, hair, and eyes, and ocular albinism (OA), which primarily involves the eyes. OCA includes several subtypes (OCA1–OCA4), each caused by different genetic mutations but often showing overlapping clinical features. OCA1 typically presents with white hair, pale skin, and light irides, while OCA2 tends to be milder and is more common in African and certain Native American populations. OCA3 presents with brown or reddish pigmentation and is more frequent in African populations, whereas OCA4 resembles OCA2 and is more common in parts of Asia. Ocular albinism, most commonly the Nettleship-Falls type, is usually X-linked and primarily affects males, with females often being carriers.
The condition occurs worldwide with an incidence of approximately 1 in 20,000 births, and about 1 in 17,000 individuals are affected by some form of albinism. Genetic inheritance for OCA is usually autosomal recessive, involving mutations in genes such as TYR, OCA2, TYRP1, and SLC45A2, while OA is typically X-linked recessive involving the GPR143 gene. The pathophysiology involves hypopigmentation of the retinal pigment epithelium during development, leading to abnormal foveal formation (macular hypoplasia), delayed retinal ganglion cell development, and misrouting of optic nerve fibers at the optic chiasm.
Clinically, patients present with a range of ocular findings including congenital nystagmus, strabismus, reduced visual acuity (typically between 20/40 and 20/400), refractive errors, amblyopia, iris transillumination, photophobia, and hypopigmented fundus with visible choroidal vasculature. Macular hypoplasia is a key feature contributing to reduced vision. Optic nerves may appear gray and may show hypoplasia. Cutaneous features in OCA include hypopigmented skin and hair, with some individuals developing freckles or nevi. A detailed history should include family history, visual symptoms, photosensitivity, and systemic features such as easy bruising or recurrent infections, which may suggest associated syndromes.
Albinism can be associated with systemic conditions such as Hermansky–Pudlak syndrome, which includes platelet dysfunction and risk of bleeding as well as pulmonary and gastrointestinal complications; Chediak–Higashi syndrome, which involves immune deficiency and recurrent infections; and Griscelli syndrome, which may include neurological or immunological abnormalities. It may also be seen in syndromes such as Prader-Willi and Angelman syndromes.
Diagnosis is primarily clinical but may be supported by genetic testing to identify specific mutations. Optical coherence tomography demonstrates macular hypoplasia, and visual evoked potential testing reveals abnormal decussation of optic nerve fibers. Skin biopsy in certain forms may show characteristic macromelanosomes. Prenatal diagnosis is possible if the genetic mutation is known.
Management is supportive and aimed at optimizing vision and protecting the skin. Refractive errors should be corrected with glasses or contact lenses, and amblyopia should be treated when present. Tinted lenses can help reduce photophobia, and low vision aids such as magnifiers and high-contrast reading materials can improve functional vision. Sun protection is essential, including the use of sunscreen and protective clothing, due to the increased risk of skin damage and malignancy.
Patients require regular follow-up with ophthalmology, low vision services, and dermatology for skin monitoring. Hematology evaluation may be necessary if syndromic associations are suspected. The overall prognosis is generally good in terms of lifespan, development, and fertility, although visual acuity remains reduced and patients are at increased risk for skin cancers such as basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.
Albinism refers to a group of inherited disorders characterized by reduced or absent melanin production due to defects in melanin synthesis or melanosome formation. It is broadly classified into oculocutaneous albinism (OCA), which affects the skin, hair, and eyes, and ocular albinism (OA), which primarily involves the eyes. OCA includes several subtypes (OCA1–OCA4), each caused by different genetic mutations but often showing overlapping clinical features. OCA1 typically presents with white hair, pale skin, and light irides, while OCA2 tends to be milder and is more common in African and certain Native American populations. OCA3 presents with brown or reddish pigmentation and is more frequent in African populations, whereas OCA4 resembles OCA2 and is more common in parts of Asia. Ocular albinism, most commonly the Nettleship-Falls type, is usually X-linked and primarily affects males, with females often being carriers.
The condition occurs worldwide with an incidence of approximately 1 in 20,000 births, and about 1 in 17,000 individuals are affected by some form of albinism. Genetic inheritance for OCA is usually autosomal recessive, involving mutations in genes such as TYR, OCA2, TYRP1, and SLC45A2, while OA is typically X-linked recessive involving the GPR143 gene. The pathophysiology involves hypopigmentation of the retinal pigment epithelium during development, leading to abnormal foveal formation (macular hypoplasia), delayed retinal ganglion cell development, and misrouting of optic nerve fibers at the optic chiasm.
Clinically, patients present with a range of ocular findings including congenital nystagmus, strabismus, reduced visual acuity (typically between 20/40 and 20/400), refractive errors, amblyopia, iris transillumination, photophobia, and hypopigmented fundus with visible choroidal vasculature. Macular hypoplasia is a key feature contributing to reduced vision. Optic nerves may appear gray and may show hypoplasia. Cutaneous features in OCA include hypopigmented skin and hair, with some individuals developing freckles or nevi. A detailed history should include family history, visual symptoms, photosensitivity, and systemic features such as easy bruising or recurrent infections, which may suggest associated syndromes.
Albinism can be associated with systemic conditions such as Hermansky–Pudlak syndrome, which includes platelet dysfunction and risk of bleeding as well as pulmonary and gastrointestinal complications; Chediak–Higashi syndrome, which involves immune deficiency and recurrent infections; and Griscelli syndrome, which may include neurological or immunological abnormalities. It may also be seen in syndromes such as Prader-Willi and Angelman syndromes.
Diagnosis is primarily clinical but may be supported by genetic testing to identify specific mutations. Optical coherence tomography demonstrates macular hypoplasia, and visual evoked potential testing reveals abnormal decussation of optic nerve fibers. Skin biopsy in certain forms may show characteristic macromelanosomes. Prenatal diagnosis is possible if the genetic mutation is known.
Management is supportive and aimed at optimizing vision and protecting the skin. Refractive errors should be corrected with glasses or contact lenses, and amblyopia should be treated when present. Tinted lenses can help reduce photophobia, and low vision aids such as magnifiers and high-contrast reading materials can improve functional vision. Sun protection is essential, including the use of sunscreen and protective clothing, due to the increased risk of skin damage and malignancy.
Patients require regular follow-up with ophthalmology, low vision services, and dermatology for skin monitoring. Hematology evaluation may be necessary if syndromic associations are suspected. The overall prognosis is generally good in terms of lifespan, development, and fertility, although visual acuity remains reduced and patients are at increased risk for skin cancers such as basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.
- Published on
Ophthalmology – Aicardi Syndrome
Aicardi syndrome is a rare genetic neurodevelopmental disorder classically defined by a triad of infantile spasms, agenesis of the corpus callosum, and distinctive chorioretinal lacunae. It primarily affects females and is presumed to follow an X-linked dominant inheritance pattern that is typically lethal in males, with rare surviving males often having chromosomal abnormalities such as XXY. The condition is extremely rare, with only several thousand cases reported worldwide. The exact gene responsible has not been definitively identified, and the disorder is thought to arise from a developmental defect of neuroectodermal origin.
The syndrome is associated with a wide range of ocular and systemic abnormalities. The hallmark ocular finding is chorioretinal lacunae, which are areas of retinal pigment epithelium and choroidal atrophy with disrupted overlying retinal architecture. Additional ocular features may include optic disc anomalies such as coloboma or hypoplasia, microphthalmia, retinal detachment, and nystagmus. Systemically, patients often have significant central nervous system malformations, including partial or complete agenesis of the corpus callosum, cortical malformations such as polymicrogyria or pachygyria, heterotopias, intracranial cysts, ventriculomegaly, and cerebral asymmetry. Other associated abnormalities include vertebral and rib malformations, hypotonia, microcephaly, dysmorphic facial features, gastrointestinal disturbances, and skin lesions. Severe developmental delay and intellectual disability are common.
Affected infants typically present between 3 and 5 months of age with neurological symptoms such as developmental delay, hypotonia, and intractable infantile spasms. Ocular findings such as decreased visual acuity, amblyopia, or strabismus may also be noted. Diagnosis is based on clinical features, with the presence of the classic triad being diagnostic. Cases with two components of the triad plus additional major or supporting features are strongly suggestive. Neuroimaging, particularly MRI, is essential to identify structural brain abnormalities, and EEG often demonstrates characteristic patterns such as hypsarrhythmia associated with infantile spasms. Routine laboratory tests are typically normal, although genetic testing such as karyotyping and microarray analysis may be performed to evaluate chromosomal abnormalities.
The differential diagnosis includes other conditions with corpus callosum agenesis, neuronal migration disorders, infantile spasms of other etiologies, and syndromes with overlapping ocular or neurological findings such as oculocerebrocutaneous syndrome. Chorioretinal lacunae are considered highly characteristic of Aicardi syndrome but may rarely be seen in other conditions.
Management is supportive and multidisciplinary, focusing on seizure control and addressing developmental and systemic complications. Antiepileptic medications, particularly vigabatrin, are commonly used, and some patients may benefit from vagus nerve stimulation. Physical, occupational, and speech therapies are important for supportive care. Regular ophthalmologic follow-up is recommended, particularly if medications such as vigabatrin are used due to potential retinal toxicity. Referral to neurology and other specialties is often necessary to manage the complex needs of these patients.
Prognosis is variable but generally poor due to severe neurological impairment. Many patients have significant developmental delay and require lifelong care. Vision is often limited more by cortical visual impairment than by ocular abnormalities unless the macula is involved. Life expectancy is reduced, with many patients succumbing to complications such as intractable seizures, aspiration, or complications related to severe neurological disability, although some individuals may survive into adolescence or adulthood.
Aicardi syndrome is a rare genetic neurodevelopmental disorder classically defined by a triad of infantile spasms, agenesis of the corpus callosum, and distinctive chorioretinal lacunae. It primarily affects females and is presumed to follow an X-linked dominant inheritance pattern that is typically lethal in males, with rare surviving males often having chromosomal abnormalities such as XXY. The condition is extremely rare, with only several thousand cases reported worldwide. The exact gene responsible has not been definitively identified, and the disorder is thought to arise from a developmental defect of neuroectodermal origin.
The syndrome is associated with a wide range of ocular and systemic abnormalities. The hallmark ocular finding is chorioretinal lacunae, which are areas of retinal pigment epithelium and choroidal atrophy with disrupted overlying retinal architecture. Additional ocular features may include optic disc anomalies such as coloboma or hypoplasia, microphthalmia, retinal detachment, and nystagmus. Systemically, patients often have significant central nervous system malformations, including partial or complete agenesis of the corpus callosum, cortical malformations such as polymicrogyria or pachygyria, heterotopias, intracranial cysts, ventriculomegaly, and cerebral asymmetry. Other associated abnormalities include vertebral and rib malformations, hypotonia, microcephaly, dysmorphic facial features, gastrointestinal disturbances, and skin lesions. Severe developmental delay and intellectual disability are common.
Affected infants typically present between 3 and 5 months of age with neurological symptoms such as developmental delay, hypotonia, and intractable infantile spasms. Ocular findings such as decreased visual acuity, amblyopia, or strabismus may also be noted. Diagnosis is based on clinical features, with the presence of the classic triad being diagnostic. Cases with two components of the triad plus additional major or supporting features are strongly suggestive. Neuroimaging, particularly MRI, is essential to identify structural brain abnormalities, and EEG often demonstrates characteristic patterns such as hypsarrhythmia associated with infantile spasms. Routine laboratory tests are typically normal, although genetic testing such as karyotyping and microarray analysis may be performed to evaluate chromosomal abnormalities.
The differential diagnosis includes other conditions with corpus callosum agenesis, neuronal migration disorders, infantile spasms of other etiologies, and syndromes with overlapping ocular or neurological findings such as oculocerebrocutaneous syndrome. Chorioretinal lacunae are considered highly characteristic of Aicardi syndrome but may rarely be seen in other conditions.
Management is supportive and multidisciplinary, focusing on seizure control and addressing developmental and systemic complications. Antiepileptic medications, particularly vigabatrin, are commonly used, and some patients may benefit from vagus nerve stimulation. Physical, occupational, and speech therapies are important for supportive care. Regular ophthalmologic follow-up is recommended, particularly if medications such as vigabatrin are used due to potential retinal toxicity. Referral to neurology and other specialties is often necessary to manage the complex needs of these patients.
Prognosis is variable but generally poor due to severe neurological impairment. Many patients have significant developmental delay and require lifelong care. Vision is often limited more by cortical visual impairment than by ocular abnormalities unless the macula is involved. Life expectancy is reduced, with many patients succumbing to complications such as intractable seizures, aspiration, or complications related to severe neurological disability, although some individuals may survive into adolescence or adulthood.
- Published on
Ophthalmology – Age-Related (Senile) Retinoschisis
Age-related (senile) retinoschisis is an acquired retinal condition characterized by splitting of the neurosensory retina into two distinct layers, most commonly occurring in the peripheral retina. It is generally a benign and slowly progressive condition, often discovered incidentally during routine eye examination. The prevalence ranges from approximately 1.65% to 7% in individuals over 40 years of age, with equal distribution between males and females. It is frequently associated with hyperopia and preexisting peripheral cystoid degeneration, although the exact genetic basis remains unknown.
The condition develops as intraretinal cysts coalesce within areas of peripheral cystoid degeneration, typically beginning near the ora serrata and extending posteriorly. The splitting most often occurs in the outer plexiform layer in the typical form, while a less common reticular form involves splitting in the nerve fiber layer. Vision is usually unaffected as long as the schisis cavity remains confined to the peripheral retina. However, visual impairment can occur if the schisis extends toward the macula, which is uncommon, or if a rhegmatogenous retinal detachment develops as a complication.
Patients are usually asymptomatic, though some may report peripheral visual field defects, flashes, floaters, or rarely central vision loss if complications arise. On dilated fundus examination, the lesion appears as a smooth, dome-shaped elevation of the retina that is immobile and does not undulate with eye movement. It is often located inferotemporally and may be bilateral, though frequently asymmetric. Additional findings include peripheral cystoid degeneration anterior to the schisis, presence of inner or outer retinal holes, fine white surface dots, and sclerosed retinal vessels within the affected area. A distinguishing feature is that the inner retinal layer does not collapse with scleral depression.
Diagnosis is primarily clinical, supported by fundus examination and sometimes imaging. Fundus photography may be used to document the extent of the lesion for follow-up. Visual field testing typically reveals an absolute scotoma corresponding to the area of schisis. Optical coherence tomography can help differentiate retinoschisis from retinal detachment by demonstrating splitting of the retinal layers rather than complete separation from the retinal pigment epithelium.
The most important differential diagnosis is rhegmatogenous retinal detachment, which may appear similar but often shows additional features such as vitreous pigment or a demarcation line. Differentiation can sometimes be challenging; however, laser retinopexy produces a visible burn in retinoschisis but not in retinal detachment, and OCT provides definitive structural distinction. Other features such as mobility of the retina and collapse with scleral depression can also aid in differentiation.
Management is usually conservative, as most cases remain stable and do not significantly affect vision. Observation with periodic follow-up is the standard approach, typically every 1 to 3 years for uncomplicated cases. In cases where the schisis extends posteriorly or is associated with retinal breaks, closer monitoring is required. Intervention such as laser retinopexy or cryotherapy may be considered in select cases, although treatment is often avoided due to the low risk of progression and the potential to induce complications. If a rhegmatogenous retinal detachment develops, surgical repair with scleral buckle or pars plana vitrectomy is indicated.
The prognosis is generally excellent, with most patients maintaining stable vision over time. However, outcomes may worsen if complications such as retinal detachment occur. Patients should be educated to seek prompt evaluation if they experience new visual symptoms such as flashes, floaters, or changes in vision. The key clinical consideration is distinguishing this condition from retinal detachment and ensuring appropriate monitoring for potential progression or complications.
Age-related (senile) retinoschisis is an acquired retinal condition characterized by splitting of the neurosensory retina into two distinct layers, most commonly occurring in the peripheral retina. It is generally a benign and slowly progressive condition, often discovered incidentally during routine eye examination. The prevalence ranges from approximately 1.65% to 7% in individuals over 40 years of age, with equal distribution between males and females. It is frequently associated with hyperopia and preexisting peripheral cystoid degeneration, although the exact genetic basis remains unknown.
The condition develops as intraretinal cysts coalesce within areas of peripheral cystoid degeneration, typically beginning near the ora serrata and extending posteriorly. The splitting most often occurs in the outer plexiform layer in the typical form, while a less common reticular form involves splitting in the nerve fiber layer. Vision is usually unaffected as long as the schisis cavity remains confined to the peripheral retina. However, visual impairment can occur if the schisis extends toward the macula, which is uncommon, or if a rhegmatogenous retinal detachment develops as a complication.
Patients are usually asymptomatic, though some may report peripheral visual field defects, flashes, floaters, or rarely central vision loss if complications arise. On dilated fundus examination, the lesion appears as a smooth, dome-shaped elevation of the retina that is immobile and does not undulate with eye movement. It is often located inferotemporally and may be bilateral, though frequently asymmetric. Additional findings include peripheral cystoid degeneration anterior to the schisis, presence of inner or outer retinal holes, fine white surface dots, and sclerosed retinal vessels within the affected area. A distinguishing feature is that the inner retinal layer does not collapse with scleral depression.
Diagnosis is primarily clinical, supported by fundus examination and sometimes imaging. Fundus photography may be used to document the extent of the lesion for follow-up. Visual field testing typically reveals an absolute scotoma corresponding to the area of schisis. Optical coherence tomography can help differentiate retinoschisis from retinal detachment by demonstrating splitting of the retinal layers rather than complete separation from the retinal pigment epithelium.
The most important differential diagnosis is rhegmatogenous retinal detachment, which may appear similar but often shows additional features such as vitreous pigment or a demarcation line. Differentiation can sometimes be challenging; however, laser retinopexy produces a visible burn in retinoschisis but not in retinal detachment, and OCT provides definitive structural distinction. Other features such as mobility of the retina and collapse with scleral depression can also aid in differentiation.
Management is usually conservative, as most cases remain stable and do not significantly affect vision. Observation with periodic follow-up is the standard approach, typically every 1 to 3 years for uncomplicated cases. In cases where the schisis extends posteriorly or is associated with retinal breaks, closer monitoring is required. Intervention such as laser retinopexy or cryotherapy may be considered in select cases, although treatment is often avoided due to the low risk of progression and the potential to induce complications. If a rhegmatogenous retinal detachment develops, surgical repair with scleral buckle or pars plana vitrectomy is indicated.
The prognosis is generally excellent, with most patients maintaining stable vision over time. However, outcomes may worsen if complications such as retinal detachment occur. Patients should be educated to seek prompt evaluation if they experience new visual symptoms such as flashes, floaters, or changes in vision. The key clinical consideration is distinguishing this condition from retinal detachment and ensuring appropriate monitoring for potential progression or complications.
- Published on
Ophthalmology – Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss among older adults, particularly in developed countries, and is the most common cause of legal blindness in individuals aged 65 years and older in the United States. It is broadly classified into two forms: non-exudative (“dry”) AMD, which accounts for approximately 90% of cases, and exudative (“wet”) AMD, which represents about 10% but is responsible for the majority of severe vision loss. Polypoidal choroidal vasculopathy (PCV) is a distinct clinical entity from AMD, characterized by abnormalities in the inner choroidal vasculature, including a branching network of dilated vessels that lead to serous leakage and hemorrhage. PCV is more commonly seen in Asian and African or African American populations, while it is less frequent in Caucasians.
The incidence and prevalence of AMD increase significantly with age. Early AMD rises from about 3.9% in individuals aged 43–54 years to over 20% in those older than 75 years, while late AMD has a 5-year incidence of approximately 0.9%. Overall prevalence of AMD in adults over 40 years is around 9.2%. PCV prevalence varies widely, ranging from 4% to 14%, and may be significantly higher in certain populations, such as Japanese patients diagnosed with AMD. Risk factors for AMD include advancing age, family history, Caucasian race, smoking, hypertension, hyperlipidemia, obesity, and female gender. In contrast, PCV is more strongly associated with ethnicity and age.
Genetic factors play an important role in AMD, with associations identified in genes such as complement factor H (CFH), LOC387715, and HTRA1, with certain variants significantly increasing disease risk. PCV shares some genetic associations, particularly involving LOC387715 and HTRA1. The pathophysiology of AMD is multifactorial and includes degeneration of the retinal pigment epithelium (RPE), accumulation of photoreceptor debris forming drusen, reduced choroidal circulation leading to ischemia, and genetic susceptibility. In the exudative form, abnormal choroidal neovascular membranes develop beneath the retina or RPE, causing leakage and hemorrhage. In PCV, abnormalities in the inner choroidal vasculature result in polyp-like dilations and vascular networks that leak or bleed beneath the RPE.
Patients with AMD or PCV may present with central visual disturbances such as blurring, distortion (metamorphopsia), central scotomas, or may be asymptomatic in early stages. On examination, non-exudative AMD is characterized by drusen, pigmentary changes in the RPE, and eventual retinal thinning or geographic atrophy. Exudative AMD may show subretinal or intraretinal fluid, hemorrhage, lipid exudates, pigment epithelial detachment, or retinal pigment epithelial tears. PCV should be suspected in patients with exudative maculopathy, particularly in non-Caucasian individuals, those with peripapillary lesions, or cases with minimal drusen in the fellow eye.
Diagnosis relies heavily on imaging. Optical coherence tomography (OCT) is essential for identifying fluid, retinal thickening, and monitoring disease progression. Fluorescein angiography is used to identify and characterize choroidal neovascularization in AMD. Indocyanine green angiography is particularly useful in PCV for visualizing the characteristic polypoidal vascular lesions and branching networks. These imaging modalities are also critical in guiding treatment decisions and monitoring response to therapy.
Management of AMD depends on the stage and type of disease. For exudative AMD, intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as bevacizumab and ranibizumab are the mainstay of treatment and have significantly improved visual outcomes. Additional therapies may include photodynamic therapy, thermal laser for selected cases, intravitreal steroids, or combination regimens in refractory cases. For non-exudative AMD, there is no curative treatment, but progression may be slowed with lifestyle modification and nutritional supplementation using AREDS formulations, which include vitamins C and E, zinc, beta-carotene, and copper. Risk factor modification, including smoking cessation and control of cardiovascular risk factors, is essential.
Management of PCV differs somewhat, with photodynamic therapy often playing a central role, particularly for subfoveal lesions. Anti-VEGF therapy is also used but may be less effective compared to its role in AMD, and combination therapy with anti-VEGF agents and photodynamic therapy has shown promising results. Referral to a retinal specialist is essential for both AMD and PCV to ensure appropriate diagnosis and management.
Patients require ongoing monitoring, including regular ophthalmologic evaluations and use of home Amsler grid testing to detect changes in vision. Low vision support may be necessary for those with significant visual impairment. Prognosis varies, with many patients maintaining functional vision with treatment, although both AMD and PCV can lead to progressive central vision loss. Despite this, these conditions do not affect overall lifespan or systemic health.
- Published on
Ophthalmology – Adie (Tonic) Pupil
Adie tonic pupil is a benign neurological condition characterized by idiopathic postganglionic parasympathetic denervation of the iris sphincter, followed by aberrant reinnervation. This results in a pupil that reacts poorly to light but better to near stimuli, a phenomenon known as light-near dissociation, along with slow redilation after accommodation. At initial presentation, the condition is unilateral in approximately 80% of cases, although about 4% of patients per year develop involvement of the fellow eye. The affected pupil is typically larger early on but may gradually become smaller than the normal pupil over time due to progressive miosis.
The condition has an estimated incidence of 4.7 per 100,000 per year and a prevalence of about 2 per 1,000 individuals. It is more common in females, accounting for roughly 70% of cases, and most frequently occurs in young adults, with a mean age of onset around 32 years. The underlying pathophysiology involves damage to the postganglionic parasympathetic fibers that innervate the iris sphincter, followed by aberrant regeneration of fibers originally destined for the ciliary body, leading to abnormal pupillary responses.
Adie tonic pupil is usually idiopathic, though it may be associated with systemic conditions such as Holmes-Adie syndrome, which includes diminished or absent deep tendon reflexes, and Ross syndrome, which combines tonic pupil, areflexia, and segmental loss of sweating. Patients often present with incidental anisocoria, blurred near vision due to accommodative dysfunction, and photophobia.
On examination, the affected pupil demonstrates poor or absent reaction to light but constricts more effectively with accommodation and redilates slowly. In unilateral cases, anisocoria is more pronounced in bright light than in darkness. Segmental contraction of the iris sphincter may be observed on slit-lamp examination. Approximately 10% of patients may show no light response at all. Deep tendon reflexes should be assessed to evaluate for associated syndromes. A comprehensive ophthalmic examination is essential, including evaluation of ocular motility and eyelid position, to exclude other serious conditions such as third nerve palsy or Horner syndrome.
Diagnosis is primarily clinical but can be supported by pharmacologic testing. Instillation of dilute pilocarpine (0.125%) causes constriction of the affected pupil due to denervation supersensitivity, while the normal pupil shows little or no response. This test is positive in the majority of patients. Laboratory investigations are generally unnecessary unless atypical features suggest an alternative underlying cause.
The differential diagnosis includes secondary tonic pupil due to inflammation, infection, ischemia, trauma, or generalized neuropathy, as well as physiologic anisocoria, third nerve palsy, pharmacologic dilation, and structural iris damage. Careful history and examination are essential to rule out these conditions, especially in bilateral or atypical cases.
Management is usually conservative, as the condition is benign. Dilute pilocarpine drops may be used to alleviate photophobia and improve near vision by constricting the pupil. Referral to neurology or neuro-ophthalmology may be warranted if the diagnosis is uncertain. Patients should be followed periodically, particularly in the early stages, to monitor for development of light-near dissociation or emergence of underlying systemic conditions. The prognosis is excellent, with most patients experiencing stable symptoms over time without significant visual impairment.
Adie tonic pupil is a benign neurological condition characterized by idiopathic postganglionic parasympathetic denervation of the iris sphincter, followed by aberrant reinnervation. This results in a pupil that reacts poorly to light but better to near stimuli, a phenomenon known as light-near dissociation, along with slow redilation after accommodation. At initial presentation, the condition is unilateral in approximately 80% of cases, although about 4% of patients per year develop involvement of the fellow eye. The affected pupil is typically larger early on but may gradually become smaller than the normal pupil over time due to progressive miosis.
The condition has an estimated incidence of 4.7 per 100,000 per year and a prevalence of about 2 per 1,000 individuals. It is more common in females, accounting for roughly 70% of cases, and most frequently occurs in young adults, with a mean age of onset around 32 years. The underlying pathophysiology involves damage to the postganglionic parasympathetic fibers that innervate the iris sphincter, followed by aberrant regeneration of fibers originally destined for the ciliary body, leading to abnormal pupillary responses.
Adie tonic pupil is usually idiopathic, though it may be associated with systemic conditions such as Holmes-Adie syndrome, which includes diminished or absent deep tendon reflexes, and Ross syndrome, which combines tonic pupil, areflexia, and segmental loss of sweating. Patients often present with incidental anisocoria, blurred near vision due to accommodative dysfunction, and photophobia.
On examination, the affected pupil demonstrates poor or absent reaction to light but constricts more effectively with accommodation and redilates slowly. In unilateral cases, anisocoria is more pronounced in bright light than in darkness. Segmental contraction of the iris sphincter may be observed on slit-lamp examination. Approximately 10% of patients may show no light response at all. Deep tendon reflexes should be assessed to evaluate for associated syndromes. A comprehensive ophthalmic examination is essential, including evaluation of ocular motility and eyelid position, to exclude other serious conditions such as third nerve palsy or Horner syndrome.
Diagnosis is primarily clinical but can be supported by pharmacologic testing. Instillation of dilute pilocarpine (0.125%) causes constriction of the affected pupil due to denervation supersensitivity, while the normal pupil shows little or no response. This test is positive in the majority of patients. Laboratory investigations are generally unnecessary unless atypical features suggest an alternative underlying cause.
The differential diagnosis includes secondary tonic pupil due to inflammation, infection, ischemia, trauma, or generalized neuropathy, as well as physiologic anisocoria, third nerve palsy, pharmacologic dilation, and structural iris damage. Careful history and examination are essential to rule out these conditions, especially in bilateral or atypical cases.
Management is usually conservative, as the condition is benign. Dilute pilocarpine drops may be used to alleviate photophobia and improve near vision by constricting the pupil. Referral to neurology or neuro-ophthalmology may be warranted if the diagnosis is uncertain. Patients should be followed periodically, particularly in the early stages, to monitor for development of light-near dissociation or emergence of underlying systemic conditions. The prognosis is excellent, with most patients experiencing stable symptoms over time without significant visual impairment.
- Published on
Ophthalmology – Acute Retinal Necrosis (Necrotizing Herpetic Retinitis)
Acute retinal necrosis is a severe, vision-threatening infectious retinitis caused by members of the herpes virus family, most commonly varicella zoster virus and herpes simplex virus. It is characterized by a combination of anterior uveitis, vitritis, and rapidly progressive peripheral retinal necrosis that spreads circumferentially and posteriorly, often accompanied by occlusive retinal vasculitis and a high risk of retinal detachment. Despite being a rare condition, with an estimated incidence of approximately 1 case per 1.6–2.0 million individuals, it typically affects otherwise healthy, immunocompetent individuals and shows a bimodal age distribution, most commonly occurring around ages 20 and 50.
Risk factors include a history of herpetic infections such as herpes simplex keratitis, herpes zoster ophthalmicus, cold sores, chickenpox, encephalitis, or shingles. Although immunodeficiency may contribute, most cases occur in immunocompetent patients. Genetic predispositions have been described, with certain HLA types associated with different populations and disease severity. The pathophysiology involves reactivation or primary infection of herpes viruses, which travel via axonal pathways to the retina, leading to viral replication within retinal cells. This results in full-thickness retinal necrosis, intranuclear viral inclusions, and both granulomatous and non-granulomatous inflammation affecting ocular tissues.
Patients may initially present with relatively mild symptoms such as eye redness, irritation, photophobia, floaters, and periorbital pain, although many experience sudden vision loss. On examination, there is often evidence of anterior uveitis, including keratic precipitates and inflammatory activity in the anterior chamber, as well as vitritis. Within days, characteristic posterior segment findings develop, including multifocal, well-demarcated patches of yellow-white retinal necrosis in the peripheral retina. These lesions rapidly progress circumferentially and posteriorly, often sparing the macula initially. Retinal vasculitis with vascular sheathing and hemorrhages may also be present. Over time, complications such as proliferative vitreoretinopathy lead to retinal breaks and rhegmatogenous retinal detachment, which occurs in more than half of cases, typically within one to two months. Bilateral involvement is seen in about 20% of patients at presentation, and without treatment, the second eye may become affected within months.
Diagnosis is primarily clinical, guided by established criteria that include peripheral retinal necrosis, rapid progression, occlusive vasculopathy, and significant intraocular inflammation. Laboratory confirmation can be achieved using polymerase chain reaction testing of aqueous or vitreous samples, which provides high sensitivity and specificity for identifying viral DNA. Other diagnostic methods, such as antibody testing or cultures, may support the diagnosis but are less definitive. Serial fundus photography is useful for monitoring disease progression, and careful examination of both eyes is essential due to the risk of bilateral spread.
The differential diagnosis includes other infectious and inflammatory retinal conditions such as progressive outer retinal necrosis, cytomegalovirus retinitis, toxoplasmosis, syphilitic retinitis, Behçet disease, sarcoidosis, intraocular lymphoma, and fungal endophthalmitis. Management requires urgent antiviral therapy to limit retinal destruction and reduce complications. Treatment traditionally involved intravenous acyclovir followed by prolonged oral therapy, but newer regimens include oral antivirals such as valacyclovir or famciclovir, often combined with intravitreal antiviral injections such as foscarnet or ganciclovir. Adjunctive corticosteroids are frequently used to control inflammation, and topical steroids are commonly administered for anterior segment involvement.
Patients should be urgently referred to a retinal or uveitis specialist due to the aggressive nature of the disease and the potential need for surgical intervention. Prophylactic laser retinopexy may be considered to reduce the risk of retinal detachment, although its benefit remains debated. Vitrectomy is indicated in cases of dense vitreous opacities, hemorrhage, or established retinal detachment. Close monitoring is essential, particularly during the early course, to detect progression, bilateral involvement, or complications.
The prognosis remains guarded despite advances in antiviral therapy, with many patients experiencing significant vision loss. Retinal detachment is the most common and serious complication, and visual outcomes are often poor, with a substantial proportion of patients developing vision worse than 20/200 over time. Other complications include optic nerve involvement, vitreous hemorrhage, retinal neovascularization, and eventual blindness. Early recognition and aggressive treatment are critical to improving outcomes and preserving vision.
Acute retinal necrosis is a severe, vision-threatening infectious retinitis caused by members of the herpes virus family, most commonly varicella zoster virus and herpes simplex virus. It is characterized by a combination of anterior uveitis, vitritis, and rapidly progressive peripheral retinal necrosis that spreads circumferentially and posteriorly, often accompanied by occlusive retinal vasculitis and a high risk of retinal detachment. Despite being a rare condition, with an estimated incidence of approximately 1 case per 1.6–2.0 million individuals, it typically affects otherwise healthy, immunocompetent individuals and shows a bimodal age distribution, most commonly occurring around ages 20 and 50.
Risk factors include a history of herpetic infections such as herpes simplex keratitis, herpes zoster ophthalmicus, cold sores, chickenpox, encephalitis, or shingles. Although immunodeficiency may contribute, most cases occur in immunocompetent patients. Genetic predispositions have been described, with certain HLA types associated with different populations and disease severity. The pathophysiology involves reactivation or primary infection of herpes viruses, which travel via axonal pathways to the retina, leading to viral replication within retinal cells. This results in full-thickness retinal necrosis, intranuclear viral inclusions, and both granulomatous and non-granulomatous inflammation affecting ocular tissues.
Patients may initially present with relatively mild symptoms such as eye redness, irritation, photophobia, floaters, and periorbital pain, although many experience sudden vision loss. On examination, there is often evidence of anterior uveitis, including keratic precipitates and inflammatory activity in the anterior chamber, as well as vitritis. Within days, characteristic posterior segment findings develop, including multifocal, well-demarcated patches of yellow-white retinal necrosis in the peripheral retina. These lesions rapidly progress circumferentially and posteriorly, often sparing the macula initially. Retinal vasculitis with vascular sheathing and hemorrhages may also be present. Over time, complications such as proliferative vitreoretinopathy lead to retinal breaks and rhegmatogenous retinal detachment, which occurs in more than half of cases, typically within one to two months. Bilateral involvement is seen in about 20% of patients at presentation, and without treatment, the second eye may become affected within months.
Diagnosis is primarily clinical, guided by established criteria that include peripheral retinal necrosis, rapid progression, occlusive vasculopathy, and significant intraocular inflammation. Laboratory confirmation can be achieved using polymerase chain reaction testing of aqueous or vitreous samples, which provides high sensitivity and specificity for identifying viral DNA. Other diagnostic methods, such as antibody testing or cultures, may support the diagnosis but are less definitive. Serial fundus photography is useful for monitoring disease progression, and careful examination of both eyes is essential due to the risk of bilateral spread.
The differential diagnosis includes other infectious and inflammatory retinal conditions such as progressive outer retinal necrosis, cytomegalovirus retinitis, toxoplasmosis, syphilitic retinitis, Behçet disease, sarcoidosis, intraocular lymphoma, and fungal endophthalmitis. Management requires urgent antiviral therapy to limit retinal destruction and reduce complications. Treatment traditionally involved intravenous acyclovir followed by prolonged oral therapy, but newer regimens include oral antivirals such as valacyclovir or famciclovir, often combined with intravitreal antiviral injections such as foscarnet or ganciclovir. Adjunctive corticosteroids are frequently used to control inflammation, and topical steroids are commonly administered for anterior segment involvement.
Patients should be urgently referred to a retinal or uveitis specialist due to the aggressive nature of the disease and the potential need for surgical intervention. Prophylactic laser retinopexy may be considered to reduce the risk of retinal detachment, although its benefit remains debated. Vitrectomy is indicated in cases of dense vitreous opacities, hemorrhage, or established retinal detachment. Close monitoring is essential, particularly during the early course, to detect progression, bilateral involvement, or complications.
The prognosis remains guarded despite advances in antiviral therapy, with many patients experiencing significant vision loss. Retinal detachment is the most common and serious complication, and visual outcomes are often poor, with a substantial proportion of patients developing vision worse than 20/200 over time. Other complications include optic nerve involvement, vitreous hemorrhage, retinal neovascularization, and eventual blindness. Early recognition and aggressive treatment are critical to improving outcomes and preserving vision.
- Published on
Ophthalmology – Acute Anterior Uveitis
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
Acute anterior uveitis is an inflammatory condition involving the iris alone (iritis) or both the iris and ciliary body (iridocyclitis), with a sudden onset and a limited course typically lasting from days to weeks, and by definition less than three months. It is one of the most common forms of uveitis and presents with intraocular inflammation that leads to pain, redness, photophobia, and blurred vision. The condition has an incidence of approximately 17 cases per 100,000 people and a prevalence of about 38 per 100,000 in developed countries, though these figures vary depending on geographic and population factors.
A significant proportion of cases are associated with genetic predisposition, particularly the HLA-B27 phenotype, which is present in about half of affected individuals in certain populations. The underlying pathophysiology involves inflammation of the anterior uveal tract, resulting in breakdown of the blood–aqueous barrier and accumulation of inflammatory cells and proteins in the anterior chamber. The causes are diverse and include autoimmune diseases, infections, trauma, surgery, medications, and lens-related conditions, although up to half of cases remain idiopathic.
Acute anterior uveitis is frequently associated with systemic conditions, especially HLA-B27-related diseases such as ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and inflammatory bowel disease. Other associations include sarcoidosis, syphilis, Lyme disease, tuberculosis, HIV infection, collagen vascular diseases, and juvenile idiopathic arthritis. A thorough history is essential and should explore systemic symptoms, prior episodes, medication use, infectious exposures, and family history of autoimmune or inflammatory disease.
Clinically, patients typically present with ocular pain, redness, photophobia, and decreased vision. On examination, ciliary flush is often seen, reflecting increased blood flow around the limbus. Pupillary constriction (miosis) may be present, and keratic precipitates can be observed on the corneal endothelium, appearing either fine or large “mutton-fat” deposits in granulomatous inflammation. The anterior chamber shows inflammatory cells and flare, and in some cases hypopyon may be present, particularly in HLA-B27-related disease or Behçet disease. Iris nodules, stromal atrophy from prior inflammation, and posterior synechiae (adhesions between the iris and lens) may also be observed. Intraocular pressure may be either elevated or reduced. A dilated fundus examination is necessary to exclude posterior segment involvement, which would suggest a broader classification such as panuveitis.
Investigations are guided by clinical suspicion. Laboratory testing is typically reserved for severe, recurrent, bilateral, or granulomatous cases and may include complete blood count, ESR, tuberculosis testing, syphilis serology, Lyme serology, HLA-B27 typing, ANA, ACE levels, and HIV testing. Imaging such as chest X-ray or CT scan may be used to evaluate for sarcoidosis or tuberculosis. The differential diagnosis is broad and includes idiopathic uveitis, HLA-B27-associated uveitis, infectious causes (viral, bacterial, fungal, or parasitic), sarcoidosis, Behçet disease, systemic lupus erythematosus, juvenile idiopathic arthritis, trauma-related inflammation, lens-induced uveitis, Fuchs heterochromic iridocyclitis, Posner-Schlossman syndrome, and masquerade syndromes such as leukemia or lymphoma.
Management focuses on controlling inflammation, relieving symptoms, and preventing complications. Corticosteroids are the mainstay of treatment, most commonly administered topically, with dosing depending on severity. In more severe or refractory cases, periocular or systemic corticosteroids may be required. Cycloplegic and mydriatic agents are used to relieve pain from ciliary spasm, prevent the formation of posterior synechiae, and stabilize the blood–aqueous barrier. In cases resistant to steroids or requiring long-term control, immunosuppressive agents or biologic therapies may be used in collaboration with specialists. Elevated intraocular pressure is treated with appropriate medications, avoiding prostaglandin analogues due to their potential pro-inflammatory effects, and topical NSAIDs may be used for associated cystoid macular edema.
Patients require close follow-up to monitor visual acuity, intraocular inflammation, and response to treatment. The frequency of visits and medications is gradually reduced as inflammation resolves. Complications can arise from both the disease and its treatment and include cataract formation, glaucoma due to trabecular damage or synechiae, hypotony from ciliary body dysfunction, and cystoid macular edema. With prompt diagnosis and appropriate management, most cases can be effectively controlled, although recurrence is common, particularly in patients with underlying systemic disease.
- Published on
Ophthalmology – Acne Rosacea
Acne rosacea is a chronic inflammatory acneiform disorder that primarily affects the central face, including the nose, cheeks, chin, forehead, and may also involve the eyelids and ocular surface. It commonly presents with facial flushing, persistent erythema, papules, pustules, and a sensation of burning or stinging, often accompanied by dry skin. Ocular involvement is frequent and may manifest as blepharoconjunctivitis with meibomian gland dysfunction, lid margin telangiectasia, recurrent hordeola or chalazia, conjunctival hyperemia, and irritation. In more severe cases, the cornea may be affected, leading to punctate epithelial keratitis, vascularization, infiltration, ulceration, or even perforation. Less commonly, inflammation may extend to the episclera, sclera, or iris.
Rosacea affects approximately 1 in 20 individuals, most commonly between the ages of 30 and 60 years, with no clear sex predilection. It is thought to be more prevalent in fair-skinned individuals of European or Celtic descent, although this may be underrecognized in darker skin due to masking by pigmentation. While no single causative gene has been identified, there is often a familial tendency. The exact etiology remains unclear, with proposed contributing factors including vascular dysregulation, immune and inflammatory mechanisms, environmental triggers, and possibly microorganisms such as Demodex folliculorum. Pathophysiologically, abnormal vascular responses lead to vasodilation and leakage of plasma, which promotes inflammation.
Patients often report a history of facial flushing triggered by environmental or lifestyle factors such as sun exposure, wind, extreme temperatures, exercise, stress, alcohol, or spicy foods. On examination, characteristic findings include diffuse erythema, telangiectasias, inflammatory papules and pustules, and in advanced cases, hypertrophy of sebaceous glands resulting in rhinophyma, which is thickening and purplish discoloration of the nasal skin. Ocular examination may reveal chronic eyelid inflammation, meibomian gland obstruction, and signs of conjunctival or corneal involvement.
Diagnosis is primarily clinical and does not require laboratory testing. Histopathological findings, when assessed, include vascular dilation, perivascular inflammatory infiltrates composed of lymphocytes, plasma cells, and histiocytes, and degeneration of dermal connective tissue with edema and elastosis. In rhinophyma, there is an increase in sebaceous gland tissue. Differential diagnoses include acne vulgaris, lupus erythematosus, seborrheic dermatitis, erysipelas, dermatitis, carcinoid syndrome, tuberculosis, and syphilis.
Management focuses on controlling symptoms and preventing progression, as rosacea is a chronic condition without a definitive cure. First-line treatment typically includes oral tetracyclines such as doxycycline or minocycline, which have both antimicrobial and anti-inflammatory effects. Topical therapies such as metronidazole, azelaic acid, or sodium sulfacetamide may also be used. Lid hygiene is essential in patients with ocular involvement, along with lubricants and, in some cases, short-term topical corticosteroids. More severe or refractory cases may require oral isotretinoin or procedural interventions such as electrocautery for telangiectasias.
Patients should be advised to avoid known triggers, use daily sunscreen, and adopt gentle skincare practices. Dietary modifications, including limiting spicy foods, alcohol, and hot beverages, may help reduce flare-ups. Referral to ophthalmology is important in cases with significant ocular involvement, particularly when there is corneal disease or recurrent eyelid lesions, and dermatology referral may be necessary for severe cutaneous disease or rhinophyma requiring surgical or laser treatment.
Regular follow-up is important to monitor for complications, especially corneal involvement, which can threaten vision if untreated. The overall prognosis is good with appropriate management, although symptoms tend to be chronic and relapsing. Key clinical insights include recognizing that recurrent chalazia or hordeola may indicate underlying ocular rosacea, and that long-term management often relies on a combination of topical and systemic antibiotic therapy along with lifestyle modification.
Acne rosacea is a chronic inflammatory acneiform disorder that primarily affects the central face, including the nose, cheeks, chin, forehead, and may also involve the eyelids and ocular surface. It commonly presents with facial flushing, persistent erythema, papules, pustules, and a sensation of burning or stinging, often accompanied by dry skin. Ocular involvement is frequent and may manifest as blepharoconjunctivitis with meibomian gland dysfunction, lid margin telangiectasia, recurrent hordeola or chalazia, conjunctival hyperemia, and irritation. In more severe cases, the cornea may be affected, leading to punctate epithelial keratitis, vascularization, infiltration, ulceration, or even perforation. Less commonly, inflammation may extend to the episclera, sclera, or iris.
Rosacea affects approximately 1 in 20 individuals, most commonly between the ages of 30 and 60 years, with no clear sex predilection. It is thought to be more prevalent in fair-skinned individuals of European or Celtic descent, although this may be underrecognized in darker skin due to masking by pigmentation. While no single causative gene has been identified, there is often a familial tendency. The exact etiology remains unclear, with proposed contributing factors including vascular dysregulation, immune and inflammatory mechanisms, environmental triggers, and possibly microorganisms such as Demodex folliculorum. Pathophysiologically, abnormal vascular responses lead to vasodilation and leakage of plasma, which promotes inflammation.
Patients often report a history of facial flushing triggered by environmental or lifestyle factors such as sun exposure, wind, extreme temperatures, exercise, stress, alcohol, or spicy foods. On examination, characteristic findings include diffuse erythema, telangiectasias, inflammatory papules and pustules, and in advanced cases, hypertrophy of sebaceous glands resulting in rhinophyma, which is thickening and purplish discoloration of the nasal skin. Ocular examination may reveal chronic eyelid inflammation, meibomian gland obstruction, and signs of conjunctival or corneal involvement.
Diagnosis is primarily clinical and does not require laboratory testing. Histopathological findings, when assessed, include vascular dilation, perivascular inflammatory infiltrates composed of lymphocytes, plasma cells, and histiocytes, and degeneration of dermal connective tissue with edema and elastosis. In rhinophyma, there is an increase in sebaceous gland tissue. Differential diagnoses include acne vulgaris, lupus erythematosus, seborrheic dermatitis, erysipelas, dermatitis, carcinoid syndrome, tuberculosis, and syphilis.
Management focuses on controlling symptoms and preventing progression, as rosacea is a chronic condition without a definitive cure. First-line treatment typically includes oral tetracyclines such as doxycycline or minocycline, which have both antimicrobial and anti-inflammatory effects. Topical therapies such as metronidazole, azelaic acid, or sodium sulfacetamide may also be used. Lid hygiene is essential in patients with ocular involvement, along with lubricants and, in some cases, short-term topical corticosteroids. More severe or refractory cases may require oral isotretinoin or procedural interventions such as electrocautery for telangiectasias.
Patients should be advised to avoid known triggers, use daily sunscreen, and adopt gentle skincare practices. Dietary modifications, including limiting spicy foods, alcohol, and hot beverages, may help reduce flare-ups. Referral to ophthalmology is important in cases with significant ocular involvement, particularly when there is corneal disease or recurrent eyelid lesions, and dermatology referral may be necessary for severe cutaneous disease or rhinophyma requiring surgical or laser treatment.
Regular follow-up is important to monitor for complications, especially corneal involvement, which can threaten vision if untreated. The overall prognosis is good with appropriate management, although symptoms tend to be chronic and relapsing. Key clinical insights include recognizing that recurrent chalazia or hordeola may indicate underlying ocular rosacea, and that long-term management often relies on a combination of topical and systemic antibiotic therapy along with lifestyle modification.
